دورية أكاديمية
أعرض في EDS

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.

التفاصيل البيبلوغرافية
العنوان: Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.
المؤلفون: Gooden MJ; 1] Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands [2] Department of Surgery, Translational Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Wiersma VR; Department of Surgery, Translational Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Boerma A; 1] Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands [2] Department of Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Leffers N; Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Boezen HM; Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., ten Hoor KA; Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Hollema H; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Walenkamp AM; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Daemen T; Department of Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Nijman HW; Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Bremer E; Department of Surgery, Translational Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
المصدر: British journal of cancer [Br J Cancer] 2014 Mar 18; Vol. 110 (6), pp. 1535-44. Date of Electronic Publication: 2014 Feb 11.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
مواضيع طبية MeSH: ADAM Proteins/*metabolism , Amyloid Precursor Protein Secretases/*metabolism , Chemokines, CXC/*blood , Membrane Proteins/*metabolism , Ovarian Neoplasms/*blood , Receptors, Scavenger/*blood, ADAM10 Protein ; ADAM17 Protein ; Chemokine CXCL16 ; Chemokines, CXC/biosynthesis ; Female ; Humans ; Immunohistochemistry ; Neoplasm Metastasis ; Ovarian Neoplasms/enzymology ; Ovarian Neoplasms/pathology ; Prognosis ; Prospective Studies ; Receptors, CXCR6 ; Receptors, Chemokine/biosynthesis ; Receptors, Chemokine/blood ; Receptors, Scavenger/biosynthesis ; Receptors, Virus/biosynthesis ; Receptors, Virus/blood ; Survival Analysis ; Tissue Array Analysis
مستخلص: Background: In certain cancers, expression of CXCL16 and its receptor CXCR6 associate with lymphocyte infiltration, possibly aiding anti-tumour immune response. In other cancers, CXCL16 and CXCR6 associate with pro-metastatic activity. In the current study, we aimed to characterise the role of CXCL16, sCXCL16, and CXCR6 in ovarian cancer (OC).
Methods: CXCL16/CXCR6 expression was analysed on tissue microarray containing 306 OC patient samples. Pre-treatment serum sCXCL16 was determined in 118 patients using ELISA. In vitro, (primary) OC cells were treated with an ADAM-10/ADAM-17 inhibitor (TAPI-2) and an ADAM-10-specific inhibitor (GI254023x), whereupon CXCL16 levels were evaluated on the cell membrane (immunofluorescent analysis, western blots) and in culture supernatants (ELISA). In addition, cell migration was assessed using scratch assays.
Results: sCXCL16 independently predicted for poor survival (hazard ratio=2.28, 95% confidence interval=1.29-4.02, P=0.005), whereas neither CXCL16 nor CXCR6 expression correlated with survival. Further, CXCL16/CXCR6 expression and serum sCXCL16 levels did not associate with lymphocyte infiltration. In vitro inhibition of both ADAM-17 and ADAM-10, but especially the latter, decreased CXCL16 membrane shedding and strongly reduced cell migration of A2780 and cultured primary OC-derived malignant cells.
Conclusions: High serum sCXCL16 is a prognostic marker for poor survival of OC patients, possibly reflecting ADAM-10 and ADAM-17 pro-metastatic activity. Therefore, serum sCXCL16 levels may be a pseudomarker that identifies patients with highly metastatic tumours.
References: Chin J Cancer. 2011 May;30(5):336-43. (PMID: 21527066)
J Pathol. 2006 Nov;210(3):363-73. (PMID: 16955398)
Biochimie. 2008 Feb;90(2):369-79. (PMID: 17920749)
Eur J Cancer. 1998 Aug;34(9):1334-40. (PMID: 9849413)
Int J Cancer. 2013 Jun 1;132(11):2597-605. (PMID: 23169448)
Cancer Res. 2007 May 15;67(10):4725-31. (PMID: 17510400)
J Immunol. 2004 May 15;172(10):6362-72. (PMID: 15128827)
Cancer Lett. 2009 Jun 28;279(1):108-17. (PMID: 19231068)
J Immunol. 2004 Mar 15;172(6):3678-85. (PMID: 15004171)
Cancer Res. 2008 Dec 1;68(23):9996-10003. (PMID: 19047182)
Int J Oncol. 2008 Aug;33(2):297-308. (PMID: 18636150)
Cancer Sci. 2008 Jul;99(7):1362-9. (PMID: 18452560)
Gynecol Oncol. 2003 Jul;90(1):75-82. (PMID: 12821345)
Cancer Res. 2008 Dec 15;68(24):10367-76. (PMID: 19074906)
Mol Med Rep. 2011 May-Jun;4(3):419-24. (PMID: 21468586)
Cancer Sci. 2007 May;98(5):621-8. (PMID: 17355265)
Nat Med. 1998 Jul;4(7):844-7. (PMID: 9662379)
Mol Cancer Res. 2008 Apr;6(4):546-54. (PMID: 18344492)
J Oncol. 2010;2010:426956. (PMID: 20049170)
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. (PMID: 19474385)
Hum Pathol. 2007 May;38(5):768-80. (PMID: 17306330)
Clin Cancer Res. 2008 Dec 1;14(23):7667-73. (PMID: 19047092)
Oncol Rep. 2013 Mar;29(3):975-82. (PMID: 23242131)
Immunity. 2000 Feb;12(2):121-7. (PMID: 10714678)
Ann Surg Oncol. 2012 Jul;19 Suppl 3:S518-27. (PMID: 21845497)
Eur J Cancer. 2009 Feb;45(3):478-89. (PMID: 19070478)
Biochim Biophys Acta. 2010 Aug;1806(1):42-9. (PMID: 20122997)
PLoS One. 2009 Aug 19;4(8):e6695. (PMID: 19690611)
Eur Urol. 2012 Feb;61(2):385-94. (PMID: 22079021)
Mod Pathol. 2004 Jul;17(7):790-7. (PMID: 15073602)
Lancet. 2009 Oct 17;374(9698):1371-82. (PMID: 19793610)
Cancer Immunol Immunother. 2009 Mar;58(3):449-59. (PMID: 18791714)
Clin Exp Immunol. 2011 Mar;163(3):324-32. (PMID: 21175594)
Biochem Biophys Res Commun. 2008 May 30;370(2):311-6. (PMID: 18373975)
Curr Pharm Des. 2009;15(29):3396-416. (PMID: 19860687)
Cancer Res. 2012 Jul 15;72(14):3546-56. (PMID: 22710437)
المشرفين على المادة: 0 (CXCL16 protein, human)
0 (CXCR6 protein, human)
0 (Chemokine CXCL16)
0 (Chemokines, CXC)
0 (Membrane Proteins)
0 (Receptors, CXCR6)
0 (Receptors, Chemokine)
0 (Receptors, Scavenger)
0 (Receptors, Virus)
EC 3.4.- (Amyloid Precursor Protein Secretases)
EC 3.4.24.- (ADAM Proteins)
EC 3.4.24.81 (ADAM10 Protein)
EC 3.4.24.81 (ADAM10 protein, human)
EC 3.4.24.86 (ADAM17 Protein)
EC 3.4.24.86 (ADAM17 protein, human)
تواريخ الأحداث: Date Created: 20140213 Date Completed: 20140715 Latest Revision: 20211021
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3960624
DOI: 10.1038/bjc.2014.55
PMID: 24518602
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1827
DOI:10.1038/bjc.2014.55